Manufacturers submit market authorisation application to the EMA for lumasiran for primary hyperoxaluria type 1

Lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase, has previously been granted Priority Medicines (PRIME) designation by the EMA as well as Orphan Drug Designation in the European Union.

Source:

Biospace Inc.